Angiotensin:
a target for Alzheimer's disease & CNS disorders
E Sussex, UK --- 10th September,
2002 ---
The identification of new
treatments of Alzheimer's disease, anxiety and depression remains a
clinical priority: Mental
disorders affect 44.3 million Americans in a given year. According to
analysts the current global CNS therapeutics market is estimated at $40-55
billion, accounting for around 15% of the total global pharmaceuticals
market. Affective disorders (including depression) and anxiety are amongst
the 10 leading causes of disability in the US and other developed
countries and thus represents a key component of the global CNS
therapeutics market. Despite the development of newer antidepressants and
anxiolytics, undesirable side effects remain a problem, as does the slow
onset of activity. Furthermore, approximately 30% of the population do not
respond to current therapies. Thus although the anti-depressant/anxiolytic
market is, in general, mature there is considerable therapeutic and
commercial potential attached to the development of new molecules with
novel mechanisms of action. In contrast, Alzheimer's disease occupies a
small share of the total CNS market but is currently experiencing massive
growth. Most current therapies or molecules in advanced development for
Alzheimer's disease compensate for altered neurotransmission and depend
heavily on the inhibition of cholinesterase or the modulation of
cholinergic receptors. More recent advances include the move towards
targeting amyloid and molecules that reduce production, accumulation or
toxicity of this molecule are likely to stand side by side with
cholinergic modifying molecules in future strategies for the treatment of
Alzheimer's disease.
Angiotensin II receptor antagonists have broken into
the cardiovascular arena and now represent a target for CNS disorders:
Like the CNS market, drugs that have been launched for the treatment of
hypertension are also massive revenue generators. Over the past decade,
angiotensin II receptor antagonists have gradually been cutting into the
market previously occupied by ACE inhibitors. Since the end of 2000,
clinical trial data have been released suggesting that the angiotensin II
receptor antagonists may have potential in a number of areas including
diabetes and heart failure. As a result of the improved side-effect
profile and expanded indications associated with the angiotensin II
receptor antagonists this is the only class of antihypertensive compounds
demonstrating significant growth. Current global sales are around $2
million and continue to increase by about 35% per year (based on sales
figures from 1998-2001). Identification of additional indications is
appealing since this will further boost sales.
This report overviews the proof of concept for
targeting central angiotensin receptors for the treatment of anxiety,
depression and Alzheimer's disease and therefore bridges the hypertension
and CNS markets. Such a bridge will satisfy companies with a history in
the treatment of hypertension that are looking for add indications and
value to their portfolio. Likewise this bridge will satisfy companies
involved in CNS therapeutics by identifying a promising and highly novel
target. Having established a proof of concept, this report then analyzes
current pharmaceutical activity surrounding both angiotensin and CNS
disorders and looks at trends in each, establishing how angiotensin
receptor ligands would fit into the CNS arena and conversely how CNS
indications would contribute to the angiotensin market place. Finally the
report offers strategic direction on the development of angiotensin
receptor ligands for the treatment of CNS disorders and also suggests
screening architectures and assays.
LeadDiscovery
has produced a unique report analyzing new indications for angiotensin
receptor ligands. This state of the art report describes the proof of
concept, pharmaceutical opportunities, as well as current and future drug
development strategies relating to this field. In short this dossier
offers a "one stop shop" for personnel involved in the
selection, development and commercialization of novel therapeutics.
Dossier
highlights:
- 20,000 words (approx)
- Overviews of clinical
and economic aspects of depression, anxiety and Alzheimer's disease.
- Overview of the
angiotensin system.
- Proof of concept and
strategy for exploiting the angiotensin system for CNS disorders.
- An analysis of
pharmaceutical activity surrounding antidepressant,
anxiolytic and memory
enhancing drugs.
- An analysis of
pharmaceutical activity surrounding angiotensin receptor ligands including
trend analyses, 21 drug profiles and patent activity.
- Identification of
companies involved in discovering and licensing molecules for the
treatment of either CNS disorders or angiotensin receptor ligands.
- Strategic advice for
the exploitation of the angiotensin system for CNS disorders.
- Recommended screening architecture and model selection.
- Price $499
Target
Audience: Research or Licensing
personnel from companies with a focus on Psychiatric (Anxiety &
Depression) or Aging Disorders (Alzheimer's); Cardiovascular Disorders;
Angiotensin; Drug Discovery; Lead Identification; Combinatorial or Other
Chemistry; Academic personnel wishing to commercially develop their
research in these fields.
To purchase this dossier
online - click here!
